Cutaneous Sarcoidosis
2
Pipeline Programs
2
Companies
3
Clinical Trials
2 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Small Molecule
1100%
+ 1 programs with unclassified modality
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Priovant TherapeuticsNC - Durham
1 program1
Oral BrepocitinibPhase 2Small Molecule2 trials
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
Priovant TherapeuticsOral Brepocitinib
Priovant TherapeuticsOral Brepocitinib
PfizerTofacitinib 5 mg twice daily
Clinical Trials (3)
Total enrollment: 385 patients across 3 trials
A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris
Start: Mar 2026Est. completion: Jul 2029342 patients
Phase 2/3Recruiting
A Phase 2 Study of the Safety and Efficacy of Brepocitinib in Adults With Cutaneous Sarcoidosis (BEACON)
Start: Apr 2025Est. completion: Dec 202628 patients
Phase 2Recruiting
Open-label Trial of Tofacitinib in Cutaneous Sarcoidosis and Granuloma Annulare
Start: Apr 2019Est. completion: Jun 202115 patients
Phase 1Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 actively recruiting trials targeting 385 patients
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.